- Investing Ideas
- /
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
8
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
8 companies
Everest Medicines
Market Cap: HK$24.3b
A biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.
1952
HK$74.50
7D
3.8%
1Y
268.8%
Simcere Pharmaceutical Group
Market Cap: HK$30.1b
An investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
2096
HK$12.16
7D
15.8%
1Y
115.2%
RemeGen
Market Cap: HK$42.3b
A biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States.
9995
HK$69.80
7D
9.1%
1Y
350.3%
Sichuan Kelun-Biotech Biopharmaceutical
Market Cap: HK$86.3b
A biopharmaceutical company, engages in the research and development, manufacturing, and commercialization of novel drugs in oncology, immunology, and other therapeutic areas in the People’s Republic of China and internationally.
6990
HK$377.60
7D
10.2%
1Y
139.7%
Genscript Biotech
Market Cap: HK$35.8b
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, Mainland China, Europe, Asia Pacific, and internationally.
1548
HK$16.42
7D
8.2%
1Y
22.5%
Innovent Biologics
Market Cap: HK$151.5b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally.
1801
HK$88.65
7D
8.1%
1Y
110.1%
Viva Biotech Holdings
Market Cap: HK$3.2b
An investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.
1873
HK$1.52
7D
2.7%
1Y
192.3%
Beijing Luzhu Biotechnology
Market Cap: HK$4.3b
A biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China.
2480
HK$21.50
7D
0%
1Y
-10.8%